Skip to main content
SpringerLink
Log in

Weitreichende Möglichkeiten der Impfprävention

Meningokokken-Infektion

  • Fortbildung
  • Published:
Pädiatrie Aims and scope

Invasive Erkrankungen durch Meningokokken treten bevorzugt im Säuglings- und Kleinkindesalter auf und kommen insgesamt selten vor. Infektionen durch Neisseria (N.) meningitidis (Meningokokken, Men) weisen jedoch eine hohe Krankheitslast und Sterblichkeit auf. Der Impfprävention kommt daher eine besondere Bedeutung zu

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Thompson MJ et al. (2006) Clinical recognition of meningococcal disease in children and adolescents. Lancet 367:397–403

    Article  PubMed  Google Scholar 

  2. Weltgesundheitsorganisation, Global Alert and Response: Meningococcal disease http://www.who.int/csr/disease/meningococcal/en/index.html)

  3. Hessler F (2005) Verbreitung von Meningokokken bei gesunden Trägern in Bayern: unter besonderer Berücksichtigung des hypervirulenten ET-15-Klons (http://opus.bibliothek.uni-wuerzburg.de/volltexte/2005/1473/)

  4. Cohn A, Jackson ML (2012) Meningococcal Disease. In: CDC Health Information for International Travel 2012 — „The Yellow Book“. Page last updated: January 25, 2012

  5. WHO Strategic Advisory Group of Experts on Immunization(SAGE) (2011). Meningococcal vaccines: WHO position paper. Weekly Epidemiological Record 86 (47): 389–397

    Google Scholar 

  6. RKI-Ratgeber für Ärzte (2011) Meningokokken-Erkrankungen http://www.rki.de/cln_162/nn_494546/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber__Meningokokken.html#doc200732bodyText7)

  7. Christensen H, May M, Bowen L, Hickman M, Trotter CL (2010) Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 10:853–861

    Article  PubMed  Google Scholar 

  8. Goldschneider I, Gotschlich EC, Artenstein MS (1969) Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 129:1327–1348

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Trotter C, Findlow J, Balmer P, Holland A, Barchha R, Hamer N et al. (2007) Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England. Clin Vaccine Immunol 14:863–868

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Trotter CL, Yaro S, Njanpop-Lafourcade BM, Drabo A, Kroman SS, Idohou RS et al. (2013) Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008. PLoS ONE 8:e55486

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Schmidt H (1940) Meningokokkeninfektionen. In: Grundlagen der spezifischen Therapie und Prophylaxe bakterieller Infektionskrankheiten. Bruno Schulz Verlag, Berlin, S. 335–385

    Google Scholar 

  12. Bröker M (2010) Schutz vor Meningokokken-Erkrankungen. Med Welt 159–163

  13. Snape MD, Pollard AJ (2005) Meningococcal polysaccharide- protein conjugate vaccines. Lancet Infect Dis 5: 21–30

    Article  CAS  PubMed  Google Scholar 

  14. Conterno LO, Silva Filho CR, Rüggeberg JU, Heath PT (2006). Conjugate vaccines for preventing meningococcal C meningitis and septicaemia. Cochrane Database Syst Rev 2006; 19;3: CD 001834

    Google Scholar 

  15. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME (2004). Effectiveness of meningococcal serogroup conjugate vaccine 4 years after introduction. Lancet 364: 365–367

    Article  CAS  PubMed  Google Scholar 

  16. Halperin SA, Diaz-Mitoma F, Dull P, Anemona A, Ceddia F (2010). Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers. Eur J Clin Microbiol Infect Dis 29:259–267

    Article  CAS  PubMed  Google Scholar 

  17. Klein NP, Reisinger KS, Johnston W, Odrlijn T, Gill CJ, Bedell L, Dull P (2012) Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatr Infect Dis J 31:64–71

    Article  PubMed  Google Scholar 

  18. Klein NP, Shepard J, Bedell L, Odrlijn T, Dull P (2012) Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers. Vaccine 30:3929–36

    Article  CAS  PubMed  Google Scholar 

  19. Halperin SA, Gupta A, Jeanfreau R, Klein NP, Reisinger K, Walter E, Bedell L, Gill C, Dull PM (2010) Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2–10 years of age. Vaccine 28:7865–72

    Article  CAS  PubMed  Google Scholar 

  20. Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, Dull PM (2009) Phase II comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 49:e1–10

    Article  PubMed  Google Scholar 

  21. Knuf M, Kieninger-Baum D, Habermehl P, Muttonen P, Maurer H, Vink P, Poolman J, Boutriau D (2010) A dose-range study assessing immunogenicity and saftey of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 28:744–53

    Article  CAS  PubMed  Google Scholar 

  22. Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, Tichmann-Schumann I, Maurer H, Maurer L, Fischbach T, Zinke H, Pankow-Culot H, Papaevangelou V, Bianco V, Van der Wielen M, Miller JM (2011) An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix TM hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine 2011 29:4264–73

    Article  CAS  PubMed  Google Scholar 

  23. Knuf M, Romain O, Kindler K, Walther U, Tran PM, Pankow-Culot H, Fischbach T, Kieninger-Baum D, Bianco V, Baine Y, Miller J (2013) Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vacinne (MenACWY-TT) in 2–10-year old-children: results of an open, randomised, controlled study. Eur J Pediatr 172: 601–12

    Article  PubMed Central  PubMed  Google Scholar 

  24. Bermal N, Huang LM, Dubey AO (2011) Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccines 7:239–47

    Article  CAS  Google Scholar 

  25. Fachinformation Nimenrix, April 2012, GlaxoSmithKline

  26. Klein NP, Baine Y, Bianco V, Lestrate PR, Naz A, Blatter M, Friedland LR, Miller JM (2013) One or two doses of quadrivalent meningococcal serogroups A, C, W135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children. Pediatr Infect Dis J 32:760–7

    Article  PubMed  Google Scholar 

  27. Knuf M, Baine Y, Bianco V, Boutriau, Miller JM (2012) Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children. Hum Vaccin Immunother 8:866–72

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Vesikari T, Forsten A (2012) Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers. Hum Vaccin Immunother 8:12

    Google Scholar 

  29. Diez-Domingo J, Cantarino MV, Torrenti JM, Sansano MI, Rosich AJ, Merino AH, de Miguel AG, Gonzalez JB, Marcos MD (2010) A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatr Infect Dis J 29:148–52

    Article  PubMed  Google Scholar 

  30. Fachinformation Menveo, Juni 2012, Novartis

  31. Dittmann (2012) Meningokokken-Erkrankungen. In: Dittmann S (Hrsgb.) Handbuch der Impfpraxis: 216

  32. Bai et al. (2011) Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin. Biol. Ther. 11(7): 969–985)

    Article  CAS  PubMed  Google Scholar 

  33. Daten des Nationalen Referenzzentrums für Meningokokken für das Jahr 2011 (http://www.meningococcus.uni-wuerzburg.de/startseite/berichte/daten_2011/)

  34. Holst J, Martin D, Arnold R, Huergo CC, Oster P, O’Hallahan J et al. (2009) Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27 Suppl 2:B3–12

    Article  CAS  PubMed  Google Scholar 

  35. Russell JE, Jolley KA, Feavers IM, Maiden MC, Suker J (2004) PorA variable regions of Neisseria meningitidis. Emerg Infect Dis 10:674–678

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Tan LK, Carlone GM, Borrow R (2010) Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 362:1511–1520

    Article  CAS  PubMed  Google Scholar 

  37. Rappuoli R (2000) Reverse vaccinology. Curr Opin Microbiol 3:445–450

    Article  CAS  PubMed  Google Scholar 

  38. Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S et al. (2012) Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine adminstered with or without routine infant vaccinations according to different immunization schedules. JAMA 307:573–582

    Article  CAS  PubMed  Google Scholar 

  39. Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I et al. (2013) Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 381:825–35

    Article  CAS  PubMed  Google Scholar 

  40. Borrow R et al. (2006) Neisseria meningitidis group B correlates of protection and assay standardization — international meeting report Emory University, Atlanta, Georgia, United States, 16–17 March 2005. Vaccine 24:5093–107

    Article  CAS  PubMed  Google Scholar 

  41. Snape MD et al. (2010) Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 29: e71–9

    Article  PubMed  Google Scholar 

  42. Santolaya ME, O’Ryan ML, Valenzuela MT, Prado V, Vergara R, Munoz A, Toneatto D, Grana G, Wang H, Clemens R, Dull PM (2012). Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomized, observer-blind, placebo-controlled study. Lancet, 379:617–24

    Article  CAS  PubMed  Google Scholar 

  43. Bexsero Fachinformation, Januar 2013, Novartis

  44. Novartis: Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants. ClinicalTrials.gov NCT00657709. (http://clinicaltrials.gov/ct2/show/NCT00657709?term=NCT00657709&rank=1) (V72P13)

  45. Esposito S et al. (2010) Tolerability of a three-dose schedule of an investigational, multicomponent, meningococcal serogroup B vaccine and routine infant vaccines in a lot consistency trial. International Pathogenic Neisseria Conferences (IPNC) 11.–16. September; Banff, Kanada. Poster #182. 30

  46. (2010) Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A; 107:19490–19495

  47. Plikaytis BD, Stella M, Boccadifuoco G, DeTora LM, Agnusdei M, Santini L et al. (2012) Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol 19:1609–1617

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  48. Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P et al. (2013) Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 13:416–25

    Article  PubMed  Google Scholar 

  49. Donnelly J (2011) Daten präsentiert bei: 11th Meeting of the European Meningococcal Disease Society (EMGM); 18-20 Mai Ljubliana, Slowenien

  50. Sheldon EA, Schwartz H, Jiang Q, Giardina PC, Perez JL (2012) A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. Hum Vaccin Immunother 8:888–95

    Article  CAS  PubMed  Google Scholar 

  51. Nissen MD, Marshall HS, Richmond PC, Jiang Q, Harris SL, Jones TR, Jansen KU, Perez JL (2013) A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J 32:364–71

    Article  PubMed  Google Scholar 

  52. Marshall HS, Richmond PC, Nissen MD, Wouters A, Baber J, Jiang Q, Anderson AS, Jones TR, Harris SL, Jansen KU, Perez JL (2013) A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine 31:1569–75

    Article  CAS  PubMed  Google Scholar 

  53. Marshall HS, Richmond PC, Nissen MD, Jiang Q, Anderson AS, Jansen KU, Reynolds G, Ziegler JB, Harris SL, Jones TR, Perez JL (2012) Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18–36 months: a phase 1 randomized-controlled clinical trial. Pediatr Infect Dis J 31:1061–8

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Kinder und Jugendliche, Dr. Horst Schmidt Klinik Wiesbaden, Ludwig-Erhard-Str. 100, 65199, Wiesbaden, Deutschland

    Markus Knuf

  2. Pädiatrische Infektiologie, Universitätsmedizin Mainz, Mainz, Deutschland

    Markus Knuf

Authors
  1. Markus Knuf
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Interessenkonflikt

Der Autor gibt folgende mögliche Interessenkonflikte an: Teilnahme als Leiter der klinischen Prüfung bzw. Principal Investigator bei klinischen Studien von GSK und Novartis, Vortrags- und Beratungstätigkeit für GSK, Baxter und Novartis gegen Honorar und Reisekostenerstattung (bis 2012).

Teile der Arbeit stützen sich auf: M. Knuf, U. Vogel. Meningokokkenimpfungen. Monatsschr Kinderheilkd 2013;161:1146–53 und M. Knuf (koordinierender Autor). Vorstellung und Bewertung eines neuen Impfstoffes gegen Meningokokken der Serogruppe B. Kinder- und Jugendarzt 2014;45:91–101

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Knuf, M. Weitreichende Möglichkeiten der Impfprävention. Pädiatrie 26 (Suppl 1), 20–27 (2014). https://doi.org/10.1007/s15014-014-0456-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15014-014-0456-7

Search

Navigation